Simply visit the free trial page here, check if your phone is compatible, and sign up using your email. After signing up you'll receive two SIM cards from Mint Mobile that will allow you to trial ...
Hosted on MSN15d
Amgen’s gMG therapy cuts disease symptoms at one-year markAmgen's research and development executive vice president Jay Bradner said: “The 52-week Mint trial results highlight the potential for a new standard of care in gMG, offering durable symptom ...
On Thursday, Amgen Inc (NASDAQ:AMGN) announced new data from the Phase 3 MINT trial of Uplizna (inebilizumab-cdon) for adult patients with generalized myasthenia gravis (gMG), a chronic autoimmune ...
A trial began March 3 to determine if tenants at Mint Urban Infinity apartments in Denver are entitled to compensation for alleged illegal and negligent actions by their landlord. Over the past ...
Data from the Phase III MINT trial found that Uplizna demonstrated a greater reduction in Myasthenia Gravis Activities of Daily Living score compared to placebo at week 26. Results from the Phase III ...
Amgen (AMGN) announced new data from the Phase 3, registrational MINT trial evaluating the efficacy and safety of Uplinza in adults living with generalized myasthenia gravis. The results ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results